Navigation Links
Experimental agent blocks prostate cancer in animal study
Date:5/22/2008

n is also professor of pharmacy and of internal medicine.

A veterinary pathologist on the study, first author Aaron Sargeant, graduate research associate in veterinary biosciences, was intrigued that adenomas occurred in the treated animals. Adenomas are not commonly found to be part of prostate-cancer development in this system, he says. This drug appears to shift tumor progression from its usual aggressive course to a more benign direction.

For this study, Chen, Sargeant, Clinton and their colleagues used a strain of transgenic mice that develops PIN at about six weeks of age, then progresses to advanced prostate cancer by 24 to 32 weeks.

The researchers added the drug to the diet of 23 of the cancer-prone mice beginning at six weeks of age, when the animals develop the precancerous condition, and continued the treatment for 18 weeks.

They then examined the animals. Of the treated mice, one showed signs of early stage cancer, but 12 still had only the precancerous condition and 10 had adenomas.

In contrast, 17 of 23 control animals developed advanced prostate cancer, two had early stage cancer, three had the precancerous condition and one an adenoma.

Experiments using a nontransgenic strain of the same mouse they do not develop prostate cancer showed that the degeneration of the testicles that accompanied the drug treatment was reversible when the drug treatment stops.

Chen noted that 186,320 cases of prostate cancer are expected this year, with 28,660 deaths from the disease. Our findings are very exciting, considering that an agent capable of reducing prostate-cancer risk by only 10 percent could prevent 18,600 cases of the disease in the United States each year, Chen says.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Experimental Drug Eases Symptoms of Mild Alzheimers
2. Experimental Blood Substitutes Unsafe, Study Finds
3. Honda to Showcase Experimental Walking Assist Device
4. Experimental Alzheimers Drug Shows Promise
5. Experimental drug shows promise in treating certain lymphomas
6. Experimental Cancer Vaccines Show Promise
7. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
8. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
9. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
10. 52 minority scientists receive travel fellowships to Experimental Biology 2008
11. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... American Diabetes Association and the CDC have released some sobering statistics ... United States. Treadmill desks offer employers an effective means of combating ... ... (Vocus) December 14, 2009 -- Rates of diabetes are climbing across ... obesity rates. Despite this rise the American Diabetes Association has stated ...
(Date:12/15/2009)... advocates to be leaders in the fight against ... from experts in online learning, the Masie Center ... ONE and Malaria No ... the first-ever "Malaria Griots" program, a dynamic education ... become leaders in the fight against malaria. ...
(Date:12/15/2009)... 4R Systems, Inc., a leading provider ... help retailers significantly increase profits by optimizing their ... that The Vitamin Shoppe has been utilizing the ... and DC inventory solutions have helped us drive ... over the last two years," said Tony Truesdale, ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will be cautioning ... matter whether there,s a public option. The current Senate ... give government authority over how your doctor treats you. ... by shifting billions of dollars from Medicare to handouts ... politicians." ,, Betsy McCaughey is the Founder/Chairman ...
(Date:12/15/2009)... 15 The new compact LifeSpan TR200 folding ... www.LifeSpanFitness.com ), was highly praised by treadmill review ... 2010. The compact TR200 folding treadmill received awards for ... under $1000. ,, The compact LifeSpan TR200 treadmill ... workout spaces. "This category buster is a very compact ...
Breaking Medicine News(10 mins):Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2
... 3 Prime Healthcare Services,Inc. (PHS) entered into a ... February 28, 2008 for all of their products,i.e., PPO, ... at any one of,PHS, hospitals* for outpatient and inpatient ... Aetna enrollees will be covered,with full in-network benefits., ...
... March 3 Aircraft Medical, the UK,medical devices ... the,prestigious 14th World Congress of Anaesthesiologists (the "Congress" ... Held every four,years, the WCA is the foremost ... Aircraft Medical sponsoring the event, but the company,s,McGRATH(R) ...
... AIDS Vaccine Initiative (IAVI) today announced the first award ... will identify and advance potential breakthrough technologies and apply ... project will apply an exciting new technology, a simulated ... which has the potential to predict human immune responses ...
... City, black babies with very low birth weights (less than ... to be born in hospitals with high risk-adjusted neonatal death ... issue of Pediatrics. White very low birth weight (VLBW) babies ... risk-adjusted neonatal death rates. In fact, only 11 percent of ...
... Eisai Corporation of,North America, its U.S. subsidiary, ... that the U.S. Food and Drug Administration,(FDA) has ... postoperative nausea and vomiting (PONV) for up to ... not been demonstrated., Aloxi, available in the ...
... ANGELES, March 2, 2008 Researchers at the University ... to develop more effective tumor vaccines by turning off ... of the study, titled A20 is an antigen presentation ... will be published in Nature Medicine on March 2, ...
Other Medicine News:Health News:Prime Healthcare Services Enters Into Network Wide Contract With Aetna Health Plans 2Health News:Aircraft Medical to Sponsor World's Premier Anaesthesiology Conference 2Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Black VLBW babies in NYC more likely to be born in hospitals with high neonatal death rates 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 3Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 4Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 5Health News:USC researchers discover novel way to develop tumor vaccines 2
(Date:12/15/2009)... Medical, Inc. (Nasdaq: NXTM ), a leading ... a group of its home hemodialysis patients and ... conventional (non-dialysis) Caribbean cruise with their NxStage® System ... Freedom Cruise: We,re Taking Home Dialysis to Sea," ... and returns on January 10, 2010. The ...
(Date:12/15/2009)... Dec. 15 Vivakor, Inc. (OTC ... divisions have reported strong performance in 2009. ... and development with divisional spokes developing multiple ... Product Pipeline strategy is anchored to the ... idea inception, Vivakor,s R&D efforts target commercialization ...
(Date:12/15/2009)... NEW HAVEN, Conn., Dec. 15 Rib-X ... development and commercialization of novel drugs for the ... has entered into a collaborative research agreement with ... the science plan for the collaboration, Dr. David ... delafloxacin, in an established animal model to determine ...
Breaking Medicine Technology:Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Vivakor Divisions Continue to Demonstrate Independent Growth 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Teenage obesity linked to increased risk of MS 10670 1Teenage obesity linked to increased risk of MS 10670 2Launching StaffingClub com a New Online Networking Platform for Recruiting and Staffing Professionals 61016 1Launching StaffingClub com a New Online Networking Platform for Recruiting and Staffing Professionals 61016 2Handwriting Skills May Lag in Kids With Autism 61014 1Handwriting Skills May Lag in Kids With Autism 61014 2
... Entrance into the Injectable Filler Market, PALO ALTO, ... launch of its Novielle Voice family of injectable fillers ... Otolaryngology -- Head,and Neck Surgery (AAO-HNS) in Chicago, IL, ... Administration (FDA) cleared Novielle Voice Gel,and Novielle Voice GelPlus ...
... Sept. 19 Enobia Pharma, an emerging biotech,company ... announced that it has received Orphan Drug designation ... ENB-0040, its enzyme,replacement therapy (ERT) for hypophosphatasia, a ... dosed the first patient in a,Phase I clinical ...
Other Medicine Technology:Coapt Systems Launches FDA Cleared Novielle Voice (TM) for Restoration of Voice Loss 2Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040 2Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040 3
Blades 4 mm...
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3...
Segment stand magnifiers come complete with bar magnifier to achieve a higher magnification while still maintaining a wide binocular field of view....
Thinprofile design eyelid implants....
Medicine Products: